Edwards Lifesciences Faces European Scrutiny Over Patent Policies, Copycat Devices
Portfolio Pulse from Vandana Singh
Edwards Lifesciences Corp (NYSE:EW) is under scrutiny by EU antitrust regulators for its patent practices and policies aimed at thwarting copycat devices. The focus is on the company's activities related to the transcatheter aortic valve replacement (TAVR) device and its global unilateral pro-innovation (anti-copycat) policy. The company's shares are down 1.02% at $70.55.
October 17, 2023 | 6:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Edwards Lifesciences is under EU antitrust scrutiny for its patent practices and anti-copycat policies, which could potentially lead to legal and financial consequences.
The scrutiny from EU antitrust regulators could lead to legal and financial consequences for Edwards Lifesciences, which could negatively impact its stock price. The company's shares have already seen a slight decrease.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100